Ottimo Pharma
Pioneering bi-functional medicines to extend the lives of people living with cancer.
- Website
- ottimopharma.com
- Last Round
- SeedDec 2024
- Rounds
- 2
About
Clinical-stage biotech developing PD-1/VEGFR2 dual-paratopic antibodies to extend lives of cancer patients.
Summary
Ottimo Pharma is a Biotech company. Its most recent funding was a Seed round in Dec 2024. Investors include Medicxi, OrbiMed and Avoro Ventures.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.